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Am J Physiol Renal Physiol 301: F1303–F1313, 2011. First published
August 31, 2011; doi:10.1152/ajprenal.00665.2010.—It was hypoth-
esized that cyclooxygenase-2 (COX-2) activity promotes urine
concentrating ability through stimulation of vasopressin (AVP)
release after water deprivation (WD). COX-2-deficient (COX-
2/, C57BL/6) and wild-type (WT) mice were water deprived for
24 h, and water balance, central AVP mRNA and peptide level, AVP
plasma concentration, and AVP-regulated renal transport protein
abundances were measured. In male COX-2/, basal urine output
and water intake were elevated while urine osmolality was decreased
compared with WT. Water deprivation resulted in lower urine osmo-
lality, higher plasma osmolality in COX-2/ mice irrespective of
gender. Hypothalamic AVP mRNA level increased and was un-
changed between COX-2/ and WT after WD. AVP peptide content
was higher in COX-2/ compared with WT. At baseline, plasma
AVP concentration was elevated in conscious chronically catheterized
COX-2/ mice, but after WD plasma AVP was unchanged between
COX-2/ and WT mice (43  11 vs. 70  16 pg/ml). Renal V2
receptor abundance was downregulated in COX-2/ mice. Medul-
lary interstitial osmolality increased and did not differ between COX-
2/ and WT after WD. Aquaporin-2 (AQP2; cortex-outer medulla),
AQP3 (all regions), and UT-A1 (inner medulla) protein abundances
were elevated in COX-2/ at baseline and further increased after
WD. COX-2/ mice had elevated plasma urea and creatinine and
accumulation of small subcapsular glomeruli. In conclusion, hypotha-
lamic COX-2 activity is not necessary for enhanced AVP expression
and secretion in response to water deprivation. Renal medullary
COX-2 activity negatively regulates AQP2 and -3. The urine concen-
trating defect in COX-2/ is likely caused by developmental glo-
merular injury and not dysregulation of AVP or collecting duct
aquaporins.
aquaporins; PGE2; water deprivation
MICE DEFICIENT IN PGE2 EP1 receptor signaling display a mild
urine concentrating defect that is coupled to a lower vasopres-
sin (AVP) mRNA level in the hypothalamus (30). However,
the source of PGE2 that potentially activates the EP1 receptor
in the neurons of hypothalamic nuclei to promote AVP expres-
sion and secretion is not clear. Cyclooxygenase type 2
(COX-2) which is expressed in the hypothalamus (10), is a
rapidly inducible enzyme isoform that is a likely candidate.
Intracerebroventricular application of the nonselective COX
inhibitor meclofenamate impairs hyperosmolality-induced
AVP secretion (49). Hypothalamic supraoptic nucleus (SON)
neurons are sensitive to experimental addition of prostanoids,
particularly PGE2 and PGF2 (46), which promotes electric
and secretory activity. It is not known whether hypothalamic
COX-2 activity is regulated by physiological variations in
plasma osmolality and supports AVP secretion. There is a
paucity of data on the role of COX-2 in the integrated control
of urinary concentration. Dietary NaCl loading, dDAVP infu-
sion, and water deprivation (WD) stimulate COX-2 expression
in renal medullary interstitial cells (29), which leads to forma-
tion of primarily PGE2 (41) and promotes interstitial cell
survival (22). Basolateral exposure of isolated collecting ducts
to PGE2 antagonizes AVP-mediated stimulation of water up-
take while it stimulates water flux in the absence of AVP (25).
COX-2-generated prostanoids promote medullary blood flow
(8) and suppresses Na-K-2Cl cotransporter (NKCC2) expres-
sion (21), which would diminish urine concentration by effects
on medullary osmolality. At the systemic level, data are also
conflicting; deletion of phopholipase A2 (12) and prostanoid
receptors (EP1, EP3) (18, 30) either had no demonstrable effect
or, paradoxically, decreased urine concentration (12), indicat-
ing that the COX pathway normally supports urine concentra-
tion. Nonselective inhibition of COX by indomethacin in-
creased sodium retention and urine concentration in one study
(1) but had the opposite effect in another study (4). Gene
deletion of COX-2 provides an alternative way to address the
issue. However, global COX-2 deletion results in developmen-
tal kidney injury with fewer cortical nephrons, while basal
diuresis and urine osmolality are not altered (40). Because no
central nervous system abnormalities have been described in
mice with disrupted COX-2 (COX-2/), we considered the
model well suited to an investigation of regulation of the
vasopressin axis by physiological challenges. The primary aim
of the present study was to elucidate the role of COX-2 in the
control of AVP expression, peptide storage, and release as well
as its effect on urine concentrating ability. Using WD as a
stimulus, mice with targeted deletion of COX-2 and their
wild-type (WT) littermates were studied to determine water
and NaCl balance, associated AVP concentrations in plasma
and hypothalamic tissue, and AVP-regulated target protein in
kidney tissue. These proteins included the V2 receptor (V2R),
NKCC2 protein, and collecting duct aquaporins (AQP2 and 3).
Because the severity of renal developmental injury is strain
specific (51), mice bred on a pure C57BL/6 background, which
have a comparably mild phenotype, were chosen for the study.
Gender differences in renal phenotype have previously been
reported in COX-2-disrupted mice (51), and therefore both
male and female mice were included.
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COX-2 knockout mice. COX-2/ mice on a mixed 129/C57BL/6
background were originally generated by Dinchuk et al. (11). The
breeder pairs were obtained from Jackson Laboratories (Bar Harbor,
ME) on a predominant C57BL6/J background. Animals were further
backcrossed to the C57BL6/J genetic background for six consecutive
generations before using them for experiments. These mice display a
mild renal injury compared with other genetic backgrounds (51).
Genotyping of COX-2 knockout mice was done as described previ-
ously (19). Mice were housed at The Biomedical Laboratory, Univer-
sity of Southern Denmark. All procedures conformed to the Danish
national guidelines for the care and handling of animals and the
published guidelines from the National Institutes of Health.
WD experiments. Nineteen wild-type and 17 COX-2/ adult mice
(8–10 wk old) were maintained in mouse metabolic cages for the
duration of the study, under controlled temperature and light condi-
tions (12:12-h light-dark cycles). The mice had free access to water
and food and were acclimatized for 3 days before the experiments.
Body weight, food intake, drinking water consumption, urine volume,
and baseline urinary osmolality were monitored for 2 consecutive
days. For WD experiments, mice were deprived by removing the
water bottles for 24 h followed by measurement of urine volume and
urinary osmolality; spot urine samples were obtained before and after
removal of water bottles. At the end of each experiment, mice were
anesthetized and blood was collected by heart puncture. Plasma was
separated by centrifugation at 3,000 g for 10 min. Plasma osmolality
was determined by freeze-point depression (Osmomat 030, Gonotec,
Berlin, Germany). Measurement of plasma sodium was done by flame
photometry (model IL 943, Instrumentation Laboratory, Lexington,
MA). Urea was determined kinetically as the amount of NADH
consumed over time measured spectrometrically (UV) after hydroly-
sis of urea by urase and the formation of L-glutamate by glutamate
dehydrogenase (ABX Pentra Urea CP, ABX Diagnostics). Plasma
concentration of creatinine was measured by application of dry matter
chemistry (Vitros 950, Johnson&Johnson).
Medullary osmolality and sodium concentration. Tissue was pro-
cessed according to a method developed by Schmidt-Nielsen et al.
(45) as modified by Fenton et al. (17). Briefly, kidneys were removed
and each individual inner medullas (IM) were rapidly excised, frozen
in liquid nitrogen, and stored at 80°C. During the analysis, IM were
placed in preweighed tubes. Samples were weighed immediately and
subsequently dried over a desiccant at 60°C for 4 h (after which
weight remained constant). After reweighing, 100 l of distilled water
was added to each tube, and tubes were capped, boiled in water bath
for 5 min, and, after brief centrifugation, stored at 4°C for 24 h for
diffusion. After centrifugation for 1 min at 8,000 g, supernatant
osmolality was determined with the osmometer (Osmomat 030, Gono-
tec, Berlin, Germany) and sodium was determined by flame photom-
etry (IL 943, flame photometer, Instrumentation Laboratory, Milan,
Italy).
Measurements of cAMP and PGE2. Urine samples were diluted in
EIA buffer and assayed directly. cAMP content was measured using
a nonradioactive enzyme immunoassay kit (Cayman Chemical, Ann
Arbor, MI).
To measure PGE2 in the brain, tissue samples were homogenized in
0.1 M phosphate buffered saline, pH 7.4, containing 1 mM EDTA and
10 M indomethacin. Urine samples were diluted in EIA buffer and
assayed directly. PGE2 was measured using a commercial enzyme
immunoassay kit (Cayman Chemical).
AVP measurement. Mice were anesthetized, and the cerebrum was
removed in total. The region containing the hypothalamus was iden-
tified by macroscopic characteristics and a tissue block of 5  5 
5 mm was removed bilaterally and snap frozen. Tissue was homog-
enized on ice in sucrose-imidazol buffer (0.3 mol/l sucrose, 25 mmol/l
imidazol, 1 mmol/l EDTA, pH adjusted to 7.2 with HCl). Before use,
the following was added: pefabloc, leupeptin, Na-ortho-vanadate,
NaF, and okadaic acid. After homogenization, the sample was cen-
trifuged at 6,000 rpm for 10 min at 4°C and the supernatant was
recovered and stored at 80°C. Protein concentration was measured
with a Bradford protein assay. Plasma was obtained from chronically
instrumented mice as described in detail below. Blood plasma and the
tissue homogenate were extracted and assayed by RIA as described
below.
Mouse plasma AVP RIA. For collection of blood samples, chronic
indwelling catheters were placed in the femoral artery as described
previously (27, 35). The catheters consisted of a Micro-renathane tip
(0.38-mm OD) connected to polyethylene tubing. Following the
operation, the catheters were attached to a swivel enabling the mice to
move freely. To maintain catheter patency, a heparin solution (100
IU/ml in isotonic glucose) was infused at 10 l/h. The mice recovered
for 4 days before the blood samples were taken. These were obtained
in heparin-coated tubes and kept on ice. Plasma was separated by
centrifugation at 4°C and stored at80°C until analysis. In all assays,
the same human plasma pool was used to determine recovery (mean
72%) and intra-assay variation (6%, n  7). Interassay variation was
5%. The RIA had a detection limit of 0.16 pg/tube (0.15 fmol/tube).
In other mammals, the physiologically relevant plasma levels include
subpicomolar concentrations (3). A 25-g mouse contains 2 ml of
blood. A priori, it was assumed that no more than 10% of blood
volume should be withdrawn from a mouse to avoid a blood pressure-
related release of AVP. From a 200-l blood sample, 80 l plasma
can be obtained. Based on this, it was assumed that plasma should be
pooled from at least three mice to provide one sample of the size
necessary to allow valid estimations of resting AVP concentrations in
the subpicomolar range. Blood samples were taken within 20 s from
the arterial catheter of conscious, undisturbed mice. We obtained 3
WT mouse plasma samples for determination of resting AVP concen-
tration by pooling 150-l blood samples from a total of 12 mice.
One plasma sample from resting COX-2/ mice was obtained by
pooling plasma from n  3 resting COX-2/ mice. The plasma
samples were extracted and assayed as described. Next, experiments
were designed to test whether consecutive sampling in the freely
moving mouse alters plasma vasopressin (n  3). Four samples of
150–180 l blood each were obtained in rapid succession from a
single mouse. Plasma was extracted and assayed as described. For
measurement of AVP after WD, a total of 26 mice (14 WT and 12
COX-2/) were implanted with catheters as described. After 4
days, mice were water deprived for 24 h and a single blood sample
of 150 l was rapidly taken. Plasma was extracted and was
pooled from two mice. This procedure yielded n  7 and n  6
independent measurements of plasma AVP in WT and COX-2/
mice, respectively, after WD.
Assay procedures were conducted essentially as described previ-
ously (5, 15). In brief, mouse plasma was extracted using Sep-Pak C18
cartridges (Waters). Samples were acidified and applied to the con-
ditioned Sep-Pak cartridges. After washing of the cartridges, the
samples were eluted using 60% ethanol in 4% acetic acid. The
samples were collected in tubes containing Triton X-100 and
evaporated to dryness under a stream of air in a 25°C water bath
overnight. The content of AVP in the extracts was measured by
conventional RIA using an antibody (AB3096) produced in this
laboratory. Samples were counted in a gamma counter (Cobra TM,
Table 1. Primer sequences for qPCR
COX-2 sense ggcgttcaactgagctgt 238 bp
COX-2 antisense ggaattctcactggcttatgtagag
AVP sense cgctctccgcttgtttcct 65 bp
AVP antisense tgggcagttctggaagtagca
18S sense ctgtggtaattctagagc 157 bp
18S antisense aggttatctagagtcacc
COX, cyclooxygenase.
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Auto Gamma, Packard). The results are not corrected for incom-
plete recovery.
Isolation of RNA and PCR. Total RNA was isolated from the
hypothalamic region using an RNeasy minikit (Qiagen). cDNA syn-
thesis, PCR analysis, and qPCR experiments were done as previously
described (39). For qPCR experiments, a standard curve was con-
structed by plotting threshold cycle (Ct values) against serial dilutions
of purified PCR product. Specificity of the product was confirmed by
postrun melting-point analysis and by gel electrophoresis. Primer
sequences are listed in Table 1.
Semiquantitative immunoblotting and immunohistochemistry. The
cortex and IM were homogenized and the homogenate was centri-
fuged at 1,000 g for 15 min at 4°C, and the supernatant was used
for immunoblotting (38). Samples were run on 9 and 12% poly-
acrylamide gels (Bio-Rad Protean II), electroeluted to nitrocellu-
lose membranes, and subjected to immunolabeling (38). For im-
munohistochemistry, the kidneys were perfusion-fixed through the
abdominal aorta and samples were prepared, embedded in paraffin,
and processed for immunohistochemistry as has been described in
detail (38) by using previously characterized antibodies. Photos
were captured with a Lecia DMRE camera (Leica Microsystem,
Herlev, Denmark) and processed using Photoshop CS5. For mor-
phometry, kidney sections labeled for AQP2 were photographed
and compound pictures of whole sections were assembled using
Photoshop CS5.
Primary antibodies. For semiquantitative immunoblotting and im-
munohistochemistry, we used specific antibodies to renal COX-1 and
COX-2 (Cayman Chemical, Ann Arbor, MI). Antibodies to AQPs,
UT-A1, V2R, and NKCC2, which had been well characterized in
previous studies, were as follows: AQP2 (H7661) (37), pSer256-
AQP2 (KO407) (9), AQP-3 (LL178AP) (13), V2R (7251AP) (16),
NKCC2 (LL320AP) (14), and UT-A1 (17).
Statistical analysis. Statistical comparisons between WT and COX-
2/ mice were analyzed by an unpaired Student’s t-test when two
groups were compared and by one-way ANOVA followed by a post
hoc unpaired Student’s t-test with Bonferroni correction when several
Table 2. Baseline measurements in male and female wild-type and COX-2/ mice
Male WT Male COX-2/ Female WT Female COX-2/
Average body weight, g/day 25.1 0.4 23.1 0.9 21.2  0.2 19.8  1.7
Food intake, g  20 g body wt1  day1 3.4  0.03 3.8 0.10 3.8  0.2 4.0  0.2
Feces, g  20 g body wt1  day1 1.9  0.03 2.1 0.06 2.2  0.17 2.09  0.2
Na	 excretion, mol  day1  20 g body wt1 90.6  4.7 201.2 33.6* 74.9 13.2 86.3  5.5
K	 excretion, mol  day1  20 g body wt1 613  16.1 710 91.4 522  35.2 555  49
Values are means  SE for n  6–10 animals/group. WT, wild-type. *P 
 0.05 vs. COX-2/.
Fig. 1. Urine concentrating ability of wild-type (WT)
and cyclooxygenase-2 knockout (COX-2/) mice.
Male and female mice were housed in metabolic cages
for 3 days before measurements. Baseline urine output
(ml·20 g body wt1·day1; A) and water intake (ml·20
g body wt1·day1; B) were measured daily. Values
are means  SE derived from 2 consecutive days
using 19 WT and 17 COX-2/ adult mice (8–10 wk
old). *P 
 0.05 comparing WT with COX-2/.
Water deprivation (WD) was initiated by removal of
water bottles from cages of WT and COX-2/ mice.
Spot urine samples were obtained at 0- and 24-h time
points. Urine osmolality was measured in both spot
urine samples and in urine samples from the urine
collection tubes. Data from male (C) and female (D)
were analyzed separately. Plasma osmolality (E) and
loss of body weight (F) were measured in both male
and female mice after 24-h WD (24h WD). Values are
means  SE of 36 mice in total. *P 
 0.05 comparing
WT with COX-2/. #P 
 0.05 comparing control
with 24h WD.
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groups were compared. P 
0.05 was taken as significant. Data are
expressed as means  SE.
RESULTS
Food and water metabolism in COX-2/ mice. There was
no difference in physical appearance, body weight at entry,
food intake, feces excretion, or behavior between adult
C57BL/6 COX-2/ mice and WT littermate controls or be-
tween genders (Table 2). At baseline, urinary sodium excretion
was significantly higher in male COX-2/ mice compared
with all other groups (Table 2). Daily urine output and water
consumption were significantly higher in male COX-2/
mice than in WT male mice (Fig. 1, A and B). Female
COX-2/ mice did not differ from WT in baseline urine
output and water consumption (Fig. 1, A and B).
Impaired urine concentrating ability in COX-2/ mice.
Baseline urine osmolality was significantly lower in male
COX-2/ mice than in WT (Fig. 1C) whereas there was no
difference between the genotypes in female mice (Fig. 1D).
Following WD, urine osmolality increased significantly in both
male and female WT mice as well as in COX-2/ mice. Male
and female COX-2/ mice achieved the same maximal urine
osmolality which was significantly lower than the value
reached in WT littermate male and female mice (Fig. 1C and
1D). Plasma osmolality was significantly higher in both male
and female COX-2/ mice compared with WT mice after
WD, and there was no difference between genders (Fig. 1E).
Relative body weight loss in response to WD did not differ
between male and female mice (Fig. 1F).
Effect of WD on AVP mRNA and peptide in hypothalamus
and plasma of WT and COX-2/ mice. In response to WD,
COX-2 mRNA abundance did not change in hypothalamic
tissue (Fig. 2A) but the PGE2 tissue concentration was higher
in COX-2/ than in WT littermates after WD (Fig. 2B).
Under baseline conditions, there was no difference between
genotypes in the AVP mRNA levels in the hypothalamus (Fig.
2C). In response to WD, AVP mRNA level increased signifi-
cantly in COX-2/ and WT mice compared with baseline
(Fig. 2C). In the control situation, hypothalamic AVP peptide
content was significantly higher in COX-2/ mice of both
genders compared with WT mice (Fig. 2D). After WD, total
AVP content did not change; i.e., the AVP peptide level in the
COX-2/ mice remained significantly higher than in WT
(Fig. 2D, genders have been pooled for clarity).
Serial plasma samples obtained from single normohydrated,
freely moving WT mice showed that the two first determina-
Fig. 2. Effect of WD on AVP concentration in
hypothalamus and plasma of WT and COX-
2/ mice. Hypothalamic regions were excised,
and total RNA was extracted. A: WT mice were
subjected to WD for 24 h, and COX-2 mRNA
level was measured by qPCR. Values are means 
SE of n  6 mice/group. B: PGE2 content in
brains from WD WT and COX-2/ mice. Val-
ues are means  SE of 11 WT and 7 COX-2/
mice. *P 
 0.05 comparing WT with COX-
2/. Hypothalamic AVP mRNA (C) and pep-
tide concentration (D) in WT and COX-2/
WD mice. Values are means  SE of 6 mice/
group. *P 
 0.05 comparing WT with COX-
2/. #P 
 0.05 comparing control with 24h
WD. E: AVP content was measured in 4 blood
samples (150–180 l), which were obtained in
rapid succession. F: plasma AVP content in
normohydrated and WD WT and COX-2/
mice. Plasma AVP content was assayed by ra-
dioimmunoassay. Values are means  SE of
normohydrated: WT n  12 (pooled from 4
separate mice 3 times) and COX-2/ n  3
(pooled from 3 separate mice 1 time) as well as
WD: WT n  14 and COX-2/ n  12 (pool
from 2 separate mice 7 and 6 times, respec-
tively) mice/group.
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tions were below the detection limit (values 
2–3 pg/ml).
AVP levels rose to 85 and 421 pg/ml in the third and fourth
sample, respectively (Fig. 2E). This pattern was observed in
three mice. Therefore, single plasma samples were pooled from
four separate mice. This was done 3 times, for a total of 12
mice. Resting plasma AVP concentration was 4.4  2 pg/ml
(Fig. 2F). Baseline plasma AVP concentration was increased in
COX-2/ mice compared with WT (Fig. 2F). After 24-h WD,
plasma AVP did not differ between the two genotypes (Fig.
2F). Of note, plasma AVP concentration in COX-2/ mice
did not change between baseline and WD although this could
not be statistically evaluated.
Effect of WD on renal IM interstitial osmolality, NKCC2,
UT-A1, and COX expressions in COX-2/ and WT mice.
COX-2/ and WT mice were used to measure IM interstitial
osmolality as well as Na	 and urea concentration. Normohy-
drated COX-2/ mice had a higher interstitial fluid osmolality
in the IM compared with WT (Fig. 3A). In response to WD,
renal IM interstitial osmolality increased significantly in both
COX-2/ and WT mice with no difference between the
genotypes (Fig. 3A). There was no difference between geno-
types in IM interstitial Na	 concentration at baseline, and it
increased to similar levels in WT and COX-2/ mice in
response to WD (Fig. 3B). Renal IM interstitial urea concen-
tration in COX-2/ was higher at baseline and increased in
both COX-2/ and WT after WD (Fig. 3B). Furthermore, the
urea transporter UT-A1 protein level was increased in IM of
COX-2/ mice compared with WT mice at baseline. In
response to WD, UT-A1 protein level was increased in WT,
but unchanged in COX-2/ mice (Fig. 3C). In normohydrated
COX-2/ mice, NKCC2 protein in cortex-outer medulla tis-
sue was reduced to 50% of that in WT mice (Fig. 3D). WD
increased NKCC2 protein abundance by a factor of 2 in WT
mice but by a factor of 5 in COX-2/ to reach a level identical
to that of WT mice (Fig. 3D). In WT mice, COX-2 protein
abundance increased by WD in IM tissue (Fig. 4A). In the
COX-2/ mice, COX-2 protein was not detectable in IM (Fig.
4B). COX-1 protein abundance was increased in IM tissue in
COX-2/ compared with WT (Fig. 4C). Baseline urinary
PGE2 excretion was similar in WT and COX-2/ and in-
creased significantly by WD in WT. This increase was absent
in COX-2/ mice (Fig. 4D).
Fig. 3. Effect of WD on renal inner medullary interstitial
osmolality, sodium and urea concentration, and expression
of urea transporter UT-A1 and Na-K-2Cl cotransporter
(NKCC2). Renal inner medullary interstitial tissue osmo-
lality (A) and sodium and urea concentration in intersti-
tial fluid (B) in WD WT and COX-2/ mice are shown.
C: immunoblot analysis for UT-A1 protein abundance in
inner medulla of control and WD WT and COX-2/
mice. D: NKCC2 expression in cortex and outer medulla
tissue in WD WT and COX-2/ mice. Values are
means  SE of n  6 mice/group. *P 
 0.05 comparing
WT with COX-2/. #P 
 0.05 comparing control with
24h WD.
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Effect of WD on cAMP level and renal AVP V2R ex-
pression. Urinary excretion of cAMP was not different
between genotypes at baseline. After WD, cAMP excretion
was significantly lower in COX-2/ than in WT mice
(Fig. 5A). V2R protein abundance in IM was significantly
decreased in COX-2/ mice compared with WT mice at
baseline and in response to WD (Fig. 5B). COX-2 deletion
had no effect on EP4 receptor transcript levels in the renal
IM (Fig. 5C).
Effect of WD on collecting duct AQP abundance and traf-
ficking in WT and COX-2/ mice. In IM, total AQP2 protein
abundance was not different between genotypes and water
regimens (Fig. 6A). pSer256-AQP2 abundance in IM was not
different between COX-2/ and WT mice at baseline (Fig.
6B). WD increased pSer256-AQP2 abundance similarly in WT
and COX-2/ in IM (Fig. 6B). Immunolabeling for total
AQP2 and pSer256-AQP2 was associated with more intense
labeling in the apical membranes of principal cells in the
COX-2/ mice compared with WT at baseline (Fig. 6, E and
I vs. C and G). WD conferred a noticeable shift of both AQP2
and pS256-AQP2 to the apical membranes in the principal cells
from COX-2/ and WT mice, and no difference in labeling
intensity was observed (Fig. 6, D–F and H–J). There was no
difference in AQP3 protein abundance in IM in response to
WD in WT mice (Fig. 7A). AQP3 protein abundance was
higher in IM in COX-2/ mice at baseline and further
increased in response to 24-h WD (Fig. 7A). Immunolabeling
for AQP3 protein was associated with the basolateral mem-
branes of principal cells, and labeling was more intense in
Fig. 5. Effect of water deprivation on urinary cAMP level and renal vasopres-
sin V2 receptor (V2R) expression. A: cAMP levels were measured in the urine
of WT and COX-2/ mice WD for 24 h. B: immunoblot analysis and
summary of all the data for V2R expression in inner medullary tissue in WD
WT and COX-2/ mice. C: qPCR of EP4 receptor mRNA levels in WD WT
and COX-2/ mice. Values are means SE of n 6 mice/group. *P
 0.05
comparing WT with COX-2/. #P 
 0.05 comparing control with 24h WD.
Fig. 4. COX expression and activity in WD WT and COX-2/ mice.
A: immunoblot analysis and summary of all the data for COX-2 expression
in inner medullary tissue in WD WT mice. B: immunoblot analysis for
COX-2 expression in inner medullary tissue in WT and COX-2/ mice.
C: immunoblot analysis and summary of all the data for COX-1 expression in
inner medullary tissue in WT and COX-2/ mice. D: urinary PGE2 excretion
in WD WT and COX-2/ mice. Values are means SE of n 6 mice/group.
*P
 0.05 comparing WT with COX-2/. #P
 0.05 comparing control with
24h WD.
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COX-2/ mice (Fig. 7, D and E vs. B and C). In the renal
cortex-outer medulla fraction, AQP2 and AQP3 protein abun-
dance was increased in normohydrated COX-2/ kidneys
compared with WT. Water deprivation increased total AQP2,
phospho-Ser256-AQP2 and AQP3 significantly in both geno-
types. Of note, AQP2 and AQP3 levels increased above levels
in water-deprived WT mice (Fig. 8).
Renal morphology in COX-2/ mice. Images of histologi-
cal sections encompassing all kidney regions including the
papilla from COX-2/ and WT mice are shown in Fig. 9. No
tissue injury was apparent in COX-2/ mice judged by the
size of the medulla, the papilla, and by the density of the
collecting ducts in the papilla outlined by immunohistochem-
ical labeling for AQP2. A rough, nonstereological, observer-
blinded counting of AQP2-positive IM collecting duct profiles
supported this observation (COX-2/: 334  41 vs. WT:
263  12, n  3/group). In the cortex, small glomeruli in the
subcapsular region and juxtamedullary glomerular hypertrophy
were observed in both male and female COX-2/ mice
compared with WT mice (Fig. 9, B and C). Plasma creatinine
and urea levels were increased in male and female COX-2/
mice compared with WT mice (14.7  2.4 vs. 7.3  1.1
mol/l, P 




The present data show that homozygous deletion of COX-2
(COX-2/) in mice attenuates urine concentrating ability and
increases hypothalamic AVP peptide content at baseline with a
preserved ability to increase hypothalamic AVP mRNA upon
WD. Plasma AVP is increased in COX-2/ mice at baseline
along with increased protein abundance of AQP2, AQP3, and
UT-A1. In response to WD, WT raised plasma AVP 12-fold
while COX-2/ mice showed no change. There was a male
propensity for increased baseline water turnover in COX-2/
mice, as previously reported (51), but the impairment in urine
concentration capacity, developmental glomerular injury, and
increased hypothalamic and plasma vasopressin as well as
plasma urea and creatinine levels were similar between genders
in COX-2/. Thus the WD challenge uncovers a similar
phenotype in male and female COX-2/ mice that is com-
pensated under baseline conditions in female mice. It has
previously been demonstrated that basal water and sodium
turnover is unaffected in COX-2/ on a mixed genetic back-
ground (40). In the study by Norwood et al. (40), genders were
not analyzed separately, which might explain the discrepancy
between the data sets. Similar to the present observation, Yang
et al. (51) observed a male propensity for kidney injury and
hypertension in COX-2/ mice. Stereological counting of
glomeruli could potentially show minor developmental injury
in females or functional differences in hormone action.
These results demonstrate that hypothalamic COX-2 activity
is not necessary for regulation of vasopressin by physiological
variations in fluid balance and that renal COX-2 activity
appears to exert a region-specific suppression of AQP2 and
AQP3. The mild defect in urine concentrating ability in COX-
Fig. 6. Renal inner medullary aquaporin-2 (AQP2) and phospho-S256AQP2 water channel abundance and trafficking in WD WT and COX-2/ mice.
Immunoblot analysis and summary of all the data for AQP2 (A) and phospho-S256AQP2 (B) expression in inner medullary tissue in WD WT and COX-2/
mice and immunolabeling for inner medullary AQP2 (C–F) and phospho-S256AQP2 (G–J) in renal sections (63 magnification) of WD WT and COX-2/
mice are shown. Values are means  SE of n  6 mice/group. #P 
 0.05 comparing control with 24h WD.
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2/ mice is likely nephrogenic and could originate from the
developmental nephron injury and increased flow in fewer
nephrons.
AVP secretion. The data show that rapid removal of 450 l
of blood from C57BL/6 mice is associated with a massive
stimulation of AVP secretion. Further blood loss up to a total
of 600–700 l blood (30% of estimated total blood volume)
increases plasma AVP by 400 times. In humans, plasma
AVP may increase by several orders of magnitude following
sudden decreases in arterial blood pressure (43, 44). Small
blood samples from single conscious mice and subsequent
pooling yielded resting AVP plasma concentrations in the
3–5 pg/ml range. Previous investigations of blood obtained
after rapid decapitation of normally hydrated, pentobarbital-
anesthetized mice have provided values of 3.3  0.6 pg/ml
(36). The present data exemplify that the resting levels of
plasma AVP in the mouse are similar to values 1 pmol/l
common to other species and that hypovolemia (most likely via
the associated hypotension) may increase the resting levels
100-fold.
Increased central AVP stores and plasma AVP in COX-2/
mice. Pituitary stores of AVP are rapidly depleted in response
to increased plasma osmolality (2). In some, but not all studies
(31, 48), PGE2 directly stimulates AVP secretion in vivo and in
vitro (23, 28), and PGE2-EP1 receptor interaction may account
for the effect (30). Since cerebral tissue PGE2 concentration
was elevated in COX-2/ mice at baseline, COX-2 is not
essential for cerebral PGE2 synthesis. The data are compatible
with an intact, and therefore COX-2-independent, central os-
mosensing mechanism. The increased total content of hypo-
thalamic AVP peptide and increased plasma AVP concentra-
tion suggest a tonically increased drive on AVP synthesis and
release in COX-2/ mice at baseline. Data are consistent with
an increased effect of AVP on the kidney in COX-2/ mice
at baseline: higher medullary interstitial osmolality, increased
accumulation of urea and higher protein abundance of UT-A1
in IM, increased protein abundance of AQP2 (cortex/outer
Fig. 7. Renal inner medullary AQP3 water channel abundance and trafficking
in WD WT and COX-2/ mice. Immunoblot analysis and summary of all the
data for AQP3 (A) expression in inner medullary tissue in WD WT and
COX-2/ mice and immunolabeling for inner medullary AQP3 (B–E) in renal
sections (63 magnification) of WD WT and COX-2/ mice are shown.
Values are means  SE of n  6 mice/group. *P 
 0.05 comparing WT with
COX-2/. #P 
 0.05 comparing control with 24h WD.
Fig. 8. Cortical and outer medullary fraction of V2R, AQP2,
phospho-Ser256-AQP2, and AQP3 water channel abundance
in WD WT and COX-2/ mice. Immunoblot analysis and
summary of all the data for V2R, AQP2, phospho-Ser256-
AQP2, and AQP3 expression in cortex and outer medullary
tissue in WD WT and COX-2/ mice are shown. Values are
means  SE of n  6 mice/group. *P 
 0.05 comparing WT
with COX-2/. #P 
 0.05 comparing control with 24h WD.
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medulla fraction) and AQP3 (cortex/outer medulla and IM),
and downregulation of the V2R (26). V2R display ligand-
mediated internalization (26), and AQP3 is regulated primarily
by long-term AVP stimulation (13). The similarity between the
plasma AVP concentrations in COX-2/ and WT mice after
WD in the face of a more severe dehydration in COX-2/
indicates a degree of AVP release impairment or a release
process running at maximal capacity. Release of AVP after
osmostimulation is under the inhibitory control of glucocorti-
coids and GABA (6, 47) which might be altered in COX-2/
mice: in addition, peripheral degradation by peptidases could
also be augmented (7, 20). The diminished urinary cAMP
excretion in COX-2/ mice despite similar AVP levels im-
plied attenuated Gs-receptor-coupled responses in the renal
medulla, whether caused by reduced abundance of the V2R or
by lower PGE2 synthesis.
COX-2 dependent regulation of AQP2 and -3. After WD,
protein abundance of total AQP2 in the cortex/outer medulla and
AQP3 in all regions was increased in COX-2/ compared with
WT mice despite similar plasma AVP levels. This difference is
therefore likely to be caused by local effects in the renal medulla.
Consistent with previous data, baseline PGE2 excretion was un-
changed in COX-2/mice (41). This could be explained by little
impact of COX-2 activity on PGE2 in mouse renal medulla at
baseline, or by increased expression of COX-1 and increased
substrate supply channeled through this pathway in the absence of
COX-2. After WD, the urinary PGE2 excretion was increased in
WT mice, but not in COX-2/ mice. Urinary PGE2 excretion is
mainly derived from medullary synthesis (34). It is concluded that
the enhanced renal medullary PGE2 synthesis after WD is medi-
ated solely by COX-2. The observations are compatible with relief
from suppression by COX-2/PGE2 of AQP2 and AQP3 in water-
deprived states in vivo. The increased medullary interstitial os-
molality could, along with elevated vasopressin, drive the upregu-
lation of AQP2 in the outer medulla from COX-2/ mice at
baseline (32).
Fig. 9. Renal morphology in WT and COX-
2/ mice. A: compound micrographs show
coronal sections of kidneys from WT (left)
and COX-2/ (right) mice labeled for
AQP2. B: cortical kidney section of male WT
mice. C: cortical kidney section of male
COX-2/ mice. The rectangular boxes en-
close glomeruli in the subcapsular and jux-
tamedullary cortical region.
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Significance of medullary interstitial fluid osmotic gradient
and morphological changes. Global disruption of COX-2 in
mice leads to a developmental shortage of last-generation
nephrons in the outermost cortex (40). This was observed also
with the present, C57BL/6 background where the kidney cor-
tex of the COX-2/ mice showed characteristic changes with
accumulation of small glomeruli in the subcapsular region.
The first-generation nephrons later become juxtamedullary
nephrons and are intact in COX-2/ mice (52). This agrees
well with the morphologically intact papilla with no difference
in the density of collecting ducts and full capacity to generate
a hypertonic interstitium in the COX-2/ mice. An elevated
interstitial osmolality was observed at baseline and was due
primarily to accumulation of urea. Baseline plasma AVP was
elevated in COX-2/ mice, and this could provide the expla-
nation. In addition, local COX-2 activity promotes medullary
blood flow (42), which counteracts accumulation and trapping
of osmolytes within the medullary interstitium.
Role of collecting duct water transport. Theoretically, a
lower density of principal cells in the COX-2/ mice could
contribute to reduced capacity for water reabsorption despite
upregulation of aquaporins, but the principal cell-selective
immunostainings for AQP2, pSer256-AQP2, and AQP3, for
example, showed no differences in cell density. Immunolabel-
ing for total AQP2 and pSer256-AQP2 showed an intact ability
to target apical principal cell membranes after WD in the IM of
COX-2/ mice. This shows that COX-2 activity is not nec-
essary for apical targeting of AQP2. Previous data have shown
that PGE2 stimulates water flux in isolated colleting ducts
when applied in the absence of AVP (24, 25). PGE2 exerts
antidiuretic effects in vivo in V2R-deficient mice via cAMP-
coupled EP4 receptors by AQP2 upregulation (33), and we
observed that the expression of the EP4 receptor is unchanged
among the WT and COX-2/ mice. COX blockers attenuate
urine concentrating ability in rats (4). Thus a PGE2-mediated
effect to stimulate hydraulic conductivity or support paracel-
lular tight junctions of collecting ducts could theoretically
contribute to the present observations in COX-2/ mice since
an abundance or targeting of aquaporins is not a likely cause of
the lower urine concentration. The collecting ducts are likely to
receive a larger flow in the COX-2/ mice with lower
nephron endowment and, in addition, COX-2/ mice have
impaired renin-angiotensin system activity (50). Together, this
could explain the lower urine concentrating ability despite
normal or augmented aquaporin levels in COX-2/ mice.
In summary, the present data show that COX-2-deficient
mice have increased hypothalamic vasopressin stores, intact
osmosensitivity of central vasopressin expression, elevated
baseline plasma AVP, an intact medullary interstitial osmotic
gradient, and unchanged or even elevated protein level of renal
AVP-regulated salt and water transport proteins. It is con-
cluded that COX-2/ mice exhibit a mild nephrogenic diabe-
tes insipidus, which we speculate is caused by hyperfiltration in
fewer nephrons and/or by lower renin-angiotensin system ac-
tivity.
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